Radioactive injection targets Hard-to-Treat tumors in new trial
NCT ID NCT06398444
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a radioactive drug called Lutetium-177 oxodotreotide in 74 people with advanced neuroendocrine tumors that have spread and are growing despite other treatments. The drug is designed to seek out and deliver radiation directly to tumor cells. Researchers are checking safety and how well it shrinks or controls the tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium-177 oxodotreotide (a radioactive drug that targets tumor cells)
What this could lead to
If successful, this could provide a new treatment option to shrink or slow growth of advanced neuroendocrine tumors that have spread and are no longer responding to other therapies.
What could go wrong
This is an early-to-mid stage trial with only 74 participants and no comparison group, so results may not be definitive. Radioactive treatment can cause side effects like kidney or bone marrow damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China